治疗淋巴畸形或孤立淋巴成分联合慢流畸形与博来霉素电硬化疗法(BEST)。

IF 1.7 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Julius Henry Loeser, Moritz Guntau, Oleksandr Bidakov, Susanne von der Heydt, Alexander Gussew, Stefan Schob, Walter A Wohlgemuth
{"title":"治疗淋巴畸形或孤立淋巴成分联合慢流畸形与博来霉素电硬化疗法(BEST)。","authors":"Julius Henry Loeser, Moritz Guntau, Oleksandr Bidakov, Susanne von der Heydt, Alexander Gussew, Stefan Schob, Walter A Wohlgemuth","doi":"10.1055/a-2648-6555","DOIUrl":null,"url":null,"abstract":"<p><p>The objective of the study was to retrospectively investigate the efficacy, technical feasibility, and patient safety of bleomycin electrosclerotherapy for lymphatic malformations and lymphatic components of combined veno-lymphatic malformations.Between May 2019 and December 2021, this retrospective, single-center study analyzed the safety and feasibility of bleomycin electrosclerotherapy in patients with lymphatic or combined veno-lymphatic malformations. The procedures, performed under imaging guidance, involved intralesional or intravenous bleomycin injection followed by reversible electroporation. Lesion sizes were measured pre- and post-treatment using T2 fatsat magnetic resonance imaging. Previous treatments, clinical symptoms, intervention details, and complications were documented and analyzed.In 21 interventions, 24 lymphatic malformations of 12 patients (mean age: 14.75 years (range: 10 days-35 years; 5 women, 7 men)) were treated. The average bleomycin dose was 3.65 mg per treatment session (range: 0.5-15 mg). Before the interventions, the mean volume of the treated malformation was 88.76 cm3 (range: 0.38-541.5 cm<sup>3</sup>) and after treatment it was 36.7 cm<sup>3</sup> (range: 0-204.97 cm<sup>3</sup>), resulting in an average volume reduction of 54.8%. Among the observed side effects, the most frequent were a temporary postinterventional local inflammatory response and temporary skin discoloration at the injection sites. An additional improvement of clinical symptoms was achieved in all patients after a mean follow-up of 8.36 months.Bleomycin electrosclerotherapy appears to be an effective, technically feasible, and safe treatment option for patients with lymphatic malformations but further studies using a prospective approach and longer post-interventional observation period in a larger study population are required. · BEST is a new therapeutic option for lymphatic malformations.. · Different needle electrodes can be used to specifically treat different types of LMs.. · Typical side effects of BEST appear to be minor, ranging from partly intentional, local inflammation to temporary skin discoloration.. · Loeser JH, Guntau M, Bidakov O et al. Therapy of lymphatic malformations or isolated lymphatic components in combined slow-flow malformations with bleomycin electrosclerotherapy (BEST). Rofo 2025; DOI 10.1055/a-2648-6555.</p>","PeriodicalId":21490,"journal":{"name":"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Therapy of lymphatic malformations or isolated lymphatic components in combined slow-flow malformations with bleomycin electrosclerotherapy (BEST).\",\"authors\":\"Julius Henry Loeser, Moritz Guntau, Oleksandr Bidakov, Susanne von der Heydt, Alexander Gussew, Stefan Schob, Walter A Wohlgemuth\",\"doi\":\"10.1055/a-2648-6555\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The objective of the study was to retrospectively investigate the efficacy, technical feasibility, and patient safety of bleomycin electrosclerotherapy for lymphatic malformations and lymphatic components of combined veno-lymphatic malformations.Between May 2019 and December 2021, this retrospective, single-center study analyzed the safety and feasibility of bleomycin electrosclerotherapy in patients with lymphatic or combined veno-lymphatic malformations. The procedures, performed under imaging guidance, involved intralesional or intravenous bleomycin injection followed by reversible electroporation. Lesion sizes were measured pre- and post-treatment using T2 fatsat magnetic resonance imaging. Previous treatments, clinical symptoms, intervention details, and complications were documented and analyzed.In 21 interventions, 24 lymphatic malformations of 12 patients (mean age: 14.75 years (range: 10 days-35 years; 5 women, 7 men)) were treated. The average bleomycin dose was 3.65 mg per treatment session (range: 0.5-15 mg). Before the interventions, the mean volume of the treated malformation was 88.76 cm3 (range: 0.38-541.5 cm<sup>3</sup>) and after treatment it was 36.7 cm<sup>3</sup> (range: 0-204.97 cm<sup>3</sup>), resulting in an average volume reduction of 54.8%. Among the observed side effects, the most frequent were a temporary postinterventional local inflammatory response and temporary skin discoloration at the injection sites. An additional improvement of clinical symptoms was achieved in all patients after a mean follow-up of 8.36 months.Bleomycin electrosclerotherapy appears to be an effective, technically feasible, and safe treatment option for patients with lymphatic malformations but further studies using a prospective approach and longer post-interventional observation period in a larger study population are required. · BEST is a new therapeutic option for lymphatic malformations.. · Different needle electrodes can be used to specifically treat different types of LMs.. · Typical side effects of BEST appear to be minor, ranging from partly intentional, local inflammation to temporary skin discoloration.. · Loeser JH, Guntau M, Bidakov O et al. Therapy of lymphatic malformations or isolated lymphatic components in combined slow-flow malformations with bleomycin electrosclerotherapy (BEST). Rofo 2025; DOI 10.1055/a-2648-6555.</p>\",\"PeriodicalId\":21490,\"journal\":{\"name\":\"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2648-6555\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2648-6555","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

本研究的目的是回顾性研究博来霉素电硬化治疗淋巴畸形和静脉-淋巴联合畸形的淋巴成分的疗效、技术可行性和患者安全性。在2019年5月至2021年12月期间,这项回顾性单中心研究分析了博来霉素电硬化治疗淋巴或联合静脉淋巴畸形患者的安全性和可行性。手术在影像学指导下进行,包括局部或静脉注射博来霉素,然后进行可逆电穿孔。使用T2脂肪卫星磁共振成像测量治疗前后病变大小。记录和分析以往的治疗、临床症状、干预细节和并发症。在21项干预措施中,治疗了12例24淋巴畸形患者(平均年龄:14.75岁(范围:10天-35岁;5名女性,7名男性)。博来霉素的平均剂量为每次治疗3.65毫克(范围:0.5-15毫克)。干预前,治疗后的畸形平均体积为88.76 cm3(范围:0.38-541.5 cm3),治疗后的畸形平均体积为36.7 cm3(范围:0-204.97 cm3),平均体积缩小54.8%。在观察到的副作用中,最常见的是介入后短暂的局部炎症反应和注射部位短暂的皮肤变色。在平均8.36个月的随访后,所有患者的临床症状都得到了进一步改善。博莱霉素电硬化治疗似乎是淋巴畸形患者的一种有效、技术上可行和安全的治疗选择,但需要在更大的研究人群中采用前瞻性方法和更长的介入后观察期进行进一步的研究。BEST是淋巴畸形的一种新的治疗选择。·不同的针电极可用于治疗不同类型的LMs。·BEST的典型副作用似乎很轻微,从部分故意的局部炎症到暂时的皮肤变色。·Loeser JH, Guntau M, Bidakov O等。治疗淋巴畸形或孤立淋巴成分联合慢流畸形与博来霉素电硬化疗法(BEST)。Rofo 2025;DOI 10.1055 / - 2648 - 6555。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Therapy of lymphatic malformations or isolated lymphatic components in combined slow-flow malformations with bleomycin electrosclerotherapy (BEST).

The objective of the study was to retrospectively investigate the efficacy, technical feasibility, and patient safety of bleomycin electrosclerotherapy for lymphatic malformations and lymphatic components of combined veno-lymphatic malformations.Between May 2019 and December 2021, this retrospective, single-center study analyzed the safety and feasibility of bleomycin electrosclerotherapy in patients with lymphatic or combined veno-lymphatic malformations. The procedures, performed under imaging guidance, involved intralesional or intravenous bleomycin injection followed by reversible electroporation. Lesion sizes were measured pre- and post-treatment using T2 fatsat magnetic resonance imaging. Previous treatments, clinical symptoms, intervention details, and complications were documented and analyzed.In 21 interventions, 24 lymphatic malformations of 12 patients (mean age: 14.75 years (range: 10 days-35 years; 5 women, 7 men)) were treated. The average bleomycin dose was 3.65 mg per treatment session (range: 0.5-15 mg). Before the interventions, the mean volume of the treated malformation was 88.76 cm3 (range: 0.38-541.5 cm3) and after treatment it was 36.7 cm3 (range: 0-204.97 cm3), resulting in an average volume reduction of 54.8%. Among the observed side effects, the most frequent were a temporary postinterventional local inflammatory response and temporary skin discoloration at the injection sites. An additional improvement of clinical symptoms was achieved in all patients after a mean follow-up of 8.36 months.Bleomycin electrosclerotherapy appears to be an effective, technically feasible, and safe treatment option for patients with lymphatic malformations but further studies using a prospective approach and longer post-interventional observation period in a larger study population are required. · BEST is a new therapeutic option for lymphatic malformations.. · Different needle electrodes can be used to specifically treat different types of LMs.. · Typical side effects of BEST appear to be minor, ranging from partly intentional, local inflammation to temporary skin discoloration.. · Loeser JH, Guntau M, Bidakov O et al. Therapy of lymphatic malformations or isolated lymphatic components in combined slow-flow malformations with bleomycin electrosclerotherapy (BEST). Rofo 2025; DOI 10.1055/a-2648-6555.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.20
自引率
5.60%
发文量
340
期刊介绍: Die RöFo veröffentlicht Originalarbeiten, Übersichtsartikel und Fallberichte aus dem Bereich der Radiologie und den weiteren bildgebenden Verfahren in der Medizin. Es dürfen nur Arbeiten eingereicht werden, die noch nicht veröffentlicht sind und die auch nicht gleichzeitig einer anderen Zeitschrift zur Veröffentlichung angeboten wurden. Alle eingereichten Beiträge unterliegen einer sorgfältigen fachlichen Begutachtung. Gegründet 1896 – nur knapp 1 Jahr nach der Entdeckung der Röntgenstrahlen durch C.W. Röntgen – blickt die RöFo auf über 100 Jahre Erfahrung als wichtigstes Publikationsmedium in der deutschsprachigen Radiologie zurück. Sie ist damit die älteste radiologische Fachzeitschrift und schafft es erfolgreich, lange Kontinuität mit dem Anspruch an wissenschaftliches Publizieren auf internationalem Niveau zu verbinden. Durch ihren zentralen Platz im Verlagsprogramm stellte die RöFo die Basis für das heute umfassende und erfolgreiche Radiologie-Medienangebot im Georg Thieme Verlag. Besonders eng verbunden ist die RöFo mit der Geschichte der Röntgengesellschaften in Deutschland und Österreich. Sie ist offizielles Organ von DRG und ÖRG und die Mitglieder der Fachgesellschaften erhalten die Zeitschrift im Rahmen ihrer Mitgliedschaft. Mit ihrem wissenschaftlichen Kernteil und dem eigenen Mitteilungsteil der Fachgesellschaften bietet die RöFo Monat für Monat ein Forum für den Austausch von Inhalten und Botschaften der radiologischen Community im deutschsprachigen Raum.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信